Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
2.
Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma [Internet]. Thyroid. 2015:567–610.CrossRef
3.
Bortot DC, Amorim BJ, Oki GC, Gapski SB, Santos AO, Lima MCL, et al. 18F-fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730–6.CrossRef
4.
Beheshti M, Mottaghy FM, Paycha F, Behrendt FFF, Van den Wyngaert T, Fogelman I, et al. (18) F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42:1767–77.CrossRef
5.
Krüger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.CrossRef
6.
Basu S, Ranade R, Thapa P. 177Lu-DOTATATE versus 177Lu-EDTMP versus cocktail/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour: can semiquantitative comparison of 68Ga-DOTATATE and 18F-fluoride PET-CT aid in personalized treatment decision making in selecting the best therapeutic option? Nucl Med Commun. 2016;37:100–2.CrossRef
7.
Duarte PS, de Castroneves LA, Sado HN, Sapienza MT, de Oliveira Hoff AAF, Buchpiguel CA. Bone and calcified soft tissue metastases of medullary thyroid carcinoma better characterized on F-fluoride PET/CT than on Ga-DOTATATE PET/CT. Nucl Med Mol Imaging. 2018;52:318–23.CrossRef
8.
do Vale RH, Marin JF, Duarte PS, Sapienza MT, Buchpiguel CA. Visualization of lymph nodal and hepatic metastases of medullary thyroid carcinoma on 18F-fluoride PET/CT. Clin Nucl Med. 2015;40:895–6.
9.
Duarte PS, Marin JFG, Filho GBC, Sapienza MT, Buchpiguel CA. 18F-fluoride uptake in soft tissue metastases of medullary thyroid carcinoma as a marker of progressive calcification. Clin Nucl Med. 2018;43:848–9.CrossRef
Metadata
Title
Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
Author
Paulo Schiavom Duarte
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04556-5

Other articles of this Issue 3/2020

European Journal of Nuclear Medicine and Molecular Imaging 3/2020 Go to the issue

Original Article

Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas

Book Review

ATLAS OF PET-CT, A Quick Guide to Image Interpretation

Original Article

Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study

Image of the Month

Extranodal involvement of multiple organs in diffuse large B cell lymphoma detected on 18F-FDG PET/CT

Original Article

Variations in radioiodine ablation: decision-making after total thyroidectomy

Short Communication

New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide